Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

Bibliography

• Gorre ME, Mohammed M, Ellwood K, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL mutation or amplification. Science 2001;293:876-80
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G, Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’. Leuk Lymphoma 2010;51:583-91
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim D-W, Issaragrisil S, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, Dasatanib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Wiesberg E, Manley PW, Breitenstein W, Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41
   PubMedGoogle Scholar
• Hazarika M, Jiang X, Liu Q, Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant or intolerant of imatinib. Clin Cancer Res 2008;14:5325-31
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2594-6
   PubMedGoogle Scholar
• Kantarjian HM, Giles F, Gattermann N, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-46
   PubMed Web of Science ®Google Scholar
• Rosti G, Palandri F, Castagnetti F, Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009;114:4933-8
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O'Brien S, Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392-7
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-caboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumour activity in preclinical assays. J Med Chem 2004;47:6658-61
   PubMed Web of Science ®Google Scholar
• Available from: http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf Tasigna Highlights of prescribing information. [Accessed 23 September 2010]
   Google Scholar
• Available from: http://www.rxlist.com/sprycel-drug.htm Sprycel. [Accessed 13 October 2010]
   Google Scholar
• Kantarijan H, Pasquini R, Levy V, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistance to imatinib at a dose of 400 to 600 milligrams daily; two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136-47
   PubMedGoogle Scholar
• Cortes JE, Jones D, O'Brien S, Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404
   PubMed Web of Science ®Google Scholar
• Manley PW, Stiefl N, Cowan-Jacob S, Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Biorg Med Chem 2010;18:6977-86
   PubMed Web of Science ®Google Scholar
• Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphic chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007;11:2289-308
   Google Scholar
• Peng B, Hayes M, Resta D, Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-42
   PubMed Web of Science ®Google Scholar
• Johnson FM, Agrawal S, Burris H, Phase I pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumours. Cancer 2010;116:1582-91
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16
   PubMed Web of Science ®Google Scholar
• Breccia M, Santopietro M, Loglisci G, Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy. Leuk Res 2010;34:e224-5
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm216218.htm FDA Nilotinib (Tasigna) [Accessed 23 September 2010]
   Google Scholar
• Available from: http://www.thestreet.com/story/10803115/sprycel174-dasatinib-receives-fda-priority-review-for-the-treatment-of-adult-patients-with-newly-diagnosed-chronic-myeloid-leukemia-cml-in-chronic-phase.html SPRYCEL (dasatinib) receives FDA priority review for the treatment of adult patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. [Accessed 23 September 2010]
   Google Scholar